ProfileGDS5678 / 1418775_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 83% 82% 82% 81% 82% 83% 83% 83% 82% 81% 82% 81% 82% 81% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.9704383
GSM967853U87-EV human glioblastoma xenograft - Control 25.9546382
GSM967854U87-EV human glioblastoma xenograft - Control 35.906982
GSM967855U87-EV human glioblastoma xenograft - Control 45.9792481
GSM967856U87-EV human glioblastoma xenograft - Control 55.9219182
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.8347183
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.954383
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.0878883
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.9248882
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.8795481
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.9466382
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.8459481
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.9687482
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.8317581